Adrenal androgens and intracrinology

Seminars in Reproductive Medicine

Volumn 22, Issue 4, 2004, Pages 299-309

  Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Androgens; Estrogens; Intracrinology; Peripheral target tissues

Indexed keywords

ANDROGEN; ANTHRACYCLINE; ANTIANDROGEN; BICALUTAMIDE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GESTAGEN; GONADORELIN AGONIST; IRINOTECAN; NAVELBINE; NILUTAMIDE; PRASTERONE; PRASTERONE SULFATE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; TRASTUZUMAB;

ADRENAL CORTEX; AGING; ANDROGEN BLOOD LEVEL; ANDROGEN SYNTHESIS; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION; CLINICAL TRIAL; COLON CANCER; COST OF ILLNESS; DRUG EFFECT; ESTROGEN RELEASE; ESTROGEN THERAPY; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; IMMUNOMODULATION; LIBIDO; LIBIDO DISORDER; LUNG CANCER; MASTALGIA; MOLECULAR MECHANICS; MUSCLE MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEBUM SECRETION; SKIN ATROPHY; STEROIDOGENESIS;

ADRENAL GLANDS; AGING; ANDROGENS; DEHYDROEPIANDROSTERONE; FEMALE; HUMANS; MALE; POSTMENOPAUSE;

EID: 11144322812     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-861547     Document Type: Review

References (82)

1. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78: C113-C118
2. Labrie F, Bélanger A, Simard J, Luu-The V, Labrie C. DHEA and peripheral androgen and estrogen formation. Intracrinology. Ann N Y Acad Sci 1995;774:16-28
3. Labrie F, Simard J, Luu-The V, et al. The 3b-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3b-HSD congenital deficiency. In: Hansson V, Levy FO, Taskén K, eds. Signal Transduction in Testicular Cells. Ernst Schering Research Foundation Workshop. New York: Springer-Verlag; 1996:185-218
4. Labrie F, Luu-The V, Lin SX, et al. The key role of 17b-HSDs in sex steroid biology. Steroids 1997;62:148-158
5. Labrie C, Bélanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1988;123:1412-1417
6. Migeon CJ, Keller AR, Lawrence B, Shepart TH II. Dehydroepiandrosterone and androsterone levels in human plasma. Effect of age and sex: day-to-day and diurnal variations. J Clin Endocrinol Metab 1957;17:1051-1062
7. Vermeulen A, Verdonck L. Radioimmunoassays of 17b-hydroxy-5a-androstan-3- one, 4-androstene-3,17-dione, dehydroepiandrosterone, 17b-hydroxyprogesterone and progesterone and its application to human male plasma. J Steroid Biochem 1976;7:1-10
8. Vermeulen A, Deslypene JP, Schelfhout W, Verdonck L, Rubens R. Adrenocortical function in old age: response to acute adrenocorticotropin stimulation. J Clin Endocrinol Metab 1982;54:187-191
9. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984;59:551-555
10. Bélanger A, Candas B, Dupont A, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994;79: 1086-1090
11. Coleman DL, Leiter EH, Schwizer RW. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 1982;31:830-833
12. Schriock ED, Buffington CK, Hubert GD, et al. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab 1988;66:1329-1331
13. Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988;66:57-61
14. MacEwen EG, Kurzman ID. Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA). J Nutr 1991;121:S51-S55
15. Tchernof A, Després JP, Bélanger A, et al. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism 1995;44:513-519
16. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78:1360-1367
17. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279-4284
18. Diamond P, Cusan L, Gomez JL, Bélanger A, Labrie F. Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J Endocrinol 1996; 150:343-850
19. Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A. Effect of 12-month DHEA replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498-3505
20. Buzdar AU, Smith R, Vogel C, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of post-menopausal patients with metastatic breast carcinoma: results of 2 randomized double-blind controlled multiinstitutional trials. Cancer 1996;77:2503-2513
21. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197
22. Peltoketo H, Isomaa V, Mäentausta O, Vihko R. Complete amino acid sequence of human placental 17b-hydroxysteroid dehydrognease deduced from cDNA. FEBS Lett 1988;239: 73-77
23. Luu-The V, Labrie C, Zhao HF, et al. Characterization of cDNAs for human estradiol 17b-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5 termini in human placenta. Mol Endocrinol 1989;3:1301-1309
24. Geissler WM, Davis DL, Wu L, et al. Male pseudohermaphroditism caused by mutations of testicular 17b-hydroxysteroid dehydrogenase 3. Nat Genet 1994;7:34-39
25. Luu-The V. Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 2001;76:143-151
26. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-182
27. Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 1999;140: 568-574
28. El-Alfy M, Luu-The V, Huang XF, et al. Localization of type 5 17b-hydroxysteroid dehydrogenase, 3 b-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 1999;140:1481-1491
29. Pelletier G, Luu-The V, El-Alfy M, Li S, Labrie F. Immunoelectron microscopic localization of 3b-hydroxysteroid dehydrogenase and type 5 17b-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J Mol Endocrinol 2001;26:11-19
30. Nokelainen P, Peltoketo H, Vihko R, Vihko P. Expression cloning of a novel estrogenic mouse 17 beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase (m17HSD7), previously described as a prolactin receptor-associated protein (PRAP) in rat. Mol Endocrinol 1998;12:1048-1059
31. He XY, Merz G, Mehta P, Schulz H, Yang SY. Human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase is a single-domain multifunctional enzyme. Characterization of a novel 17beta-hydroxysteroid dehydrogenase. J Biol Chem 1999;274:15014-15019
32. Brereton P, Suzuki T, Sasano H, et al. Pan1b (17betaHSD11)-enzymatic activity and distribution in the lung. Mol Cell Endocrinol 2001;171:111-117
33. Napoli JL. 17beta-Hydroxysteroid dehvdrogenase type 9 and other short-chain dehydrogenases/reductases that catalyze retinoid, 17beta- and 3alpha-hydroxysteroid metabolism. Mol Cell Endocrinol 2001;171:103-109
34. Cheng KC, White PC, Qin KN. Molecular cloning and expression of rat liver 3 alpha-hydroxysteroid dehydrogenase. Mol Endocrinol 1991;5:823-828
35. Dufort I, Tremblay Y, Bélanger A, Labrie F, Luu-The V. Isolation and characterization of a stereospecific 3b-hydroxysteroid sulfotransferase (pregnenolone sulfotransferase) cDNA. DNA Cell Biol 1996;15:481-487
36. Hudson RW. Comparison of 3 alpha-hydroxysteroid dehydrogenase activities in the microsomal fractions of hyperplastic, malignant and normal human prostatic tissues. J Steroid Biochem 1984;20:829-833
37. Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82:2396-2402
38. Labrie F, Belanger A, Cusan L, Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997; 82:2403-2409
39. Riggs BL, Wahner HW, Dunn WL, et al. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest 1981;67:328-335
40. Mazess RB. On aging bone loss. Clin Orthop 1982;165:239-252
41. Johnston CC Jr, Hui SL, Witt RM, et al. Early menopausal changes in bone mass and sex steroids. J Clin Endocrinol Metab 1985;61:905-911
42. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995;80:1429-1430
43. Grodin JM, Siiteri PK, McDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973;36:207-214
44. Steinberg KK, Freni-Titulaer LW, DePuey EG, et al. Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 1989;69:533-539
45. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 2001;56:361-376
46. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-160
47. Sherwin BB. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord 1988;14:177-187
48. Notelovitz M, Watts N, Timmons C, et al. Effects of Estrogen Plus Low Dose Androgen Versus Estrogen Alone on Menopausal Symptoms in Oophorectomized/Hysterectomized Women. Montreal: North American Menopause Society; 1991
49. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal women. The importance of sexual activity and hormones. JAMA 1983;249: 2195-2198
50. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397-409
51. Pye JK, Mansel RE, Hughes LE. Clinical experience of drug treatments for mastalgia. Lancet 1985;2:373-377
52. DeFazio J, Meldrum DR, Winer JH, Judd HL. Direct action of androgen on hot flushes in the human male. Maturitas 1984;6:3-8
53. Sherwin BB, Gelfand MM. Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause. Am J Obstet Gynecol 1984;148:552-557
54. Schwartz AG, Pashko L, Whitcomb JM. Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol 1986;14:357-362
55. Gordon GB, Shantz LM, Talalay P. Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone. Adv Enzyme Regul 1987;26:355-382
56. Li S, Yan X, Bélanger A, Labrie F. Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res Treat 1993;29:203-217
57. Suzuki T, Suzuki N, Daynes RA, Engleman EG. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 1991;61:202-211
58. Rasmussen KR, Arrowood MJ, Healey MC. Effectiveness of dehydroepiandrosterone in reduction of cryptosporidial activity in immunosuppressed rats. Antimicrob Agents Chemother 1992;36:220-222
59. Henderson E, Yang JY, Schwartz A. Dehydroepiandrosterone (DHEA) and sysnthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication. AIDS Res Hum Retroviruses 1992;8:625-631
60. Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 1993;169:1536-1539
61. Labrie F, Luu-The V, Lin S-X, Simard J, Labrie C. Role of 17b-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol Metab 2000;11:421-427
62. Labrie F, Dupont A, Bélanger A, et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982; 5:267-275
63. Labrie F, Dupont A, Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In: de Vita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology Philadelphia: J.B. Lippincott; 1985:193-217
64. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424
65. Denis L, Carnelro de Moura J, Bono A, et al. Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993;42:119-129
66. Bennett CL, Tosteson TD, Schmitt B, et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using Flutamide. Prostate Cancer Prostatic Dis 1999;2:4-8
67. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int 2001;87:806-813
68. Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001; 57:727-732
69. Aprikian AG, Fleshner N, Langleben A, Hames J. An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer. Can J Urol 2003;10:1986-1994
70. Klotz LH. Selling ourselves short. Can J Urol 2003;10:1969
71. Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149:77-83
72. Caubet JF, Tosteson TD, Dong EW, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997;49:71-78
73. Dijkman GA, Janknegt RA, Dereijke TM, Debruyne FMJ. Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. J Urol 1997;158: 160-163
74. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. Eur Urol 1998;33:144-151
75. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-1498
76. Debruyne F, Delaere P, Vander Poorten V. Postoperative course of serum parathyroid hormone and calcium after surgery for primary hyperparathyroidism. Acta Otorhinolaryngol Belg 2001;55:153-157
77. Labrie F, Bélanger A, Cusan L, et al. History of LHRH agonists and combination therapy in prostate cancer. Endocr Relat Cancer 1996;3:243-278
78. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 2002;60:115-119
79. Labrie F, Champagne P, Labrie C, et al. Activity and safety of the orally active pure antiestrogen EM-800 (SCH 57050) in Tamoxifen-resistant breast cancer. J Clin Oncol 2004;22:864-871
80. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224
81. Soloway MS, Ishikawa S, Van der Zwang R, Todd B. Prognostic factors in patients with advanced prostate cancer. Urology 1989;33:53-56
82. Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 2001;6: 177-182